ATE374204T1 - Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen - Google Patents

Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen

Info

Publication number
ATE374204T1
ATE374204T1 AT02749055T AT02749055T ATE374204T1 AT E374204 T1 ATE374204 T1 AT E374204T1 AT 02749055 T AT02749055 T AT 02749055T AT 02749055 T AT02749055 T AT 02749055T AT E374204 T1 ATE374204 T1 AT E374204T1
Authority
AT
Austria
Prior art keywords
thienopyrimidinedione
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
AT02749055T
Other languages
English (en)
Inventor
Rachel Reynolds
Anthony Ingall
Rukhsana Rasul
Simon Guile
Martin Cooper
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE374204T1 publication Critical patent/ATE374204T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
AT02749055T 2001-07-28 2002-07-24 Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen ATE374204T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0118479.5A GB0118479D0 (en) 2001-07-28 2001-07-28 Novel compounds

Publications (1)

Publication Number Publication Date
ATE374204T1 true ATE374204T1 (de) 2007-10-15

Family

ID=9919407

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749055T ATE374204T1 (de) 2001-07-28 2002-07-24 Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen

Country Status (24)

Country Link
US (2) US7384950B2 (de)
EP (1) EP1414825B9 (de)
JP (1) JP4456364B2 (de)
KR (1) KR100897469B1 (de)
CN (1) CN1324033C (de)
AR (1) AR038000A1 (de)
AT (1) ATE374204T1 (de)
AU (1) AU2002319469B2 (de)
BR (1) BR0211262A (de)
CA (1) CA2453274A1 (de)
DE (1) DE60222671T2 (de)
ES (1) ES2292784T3 (de)
GB (1) GB0118479D0 (de)
HU (1) HUP0402336A3 (de)
IL (2) IL159785A0 (de)
IS (1) IS2598B (de)
MX (1) MXPA04000677A (de)
MY (1) MY138145A (de)
NO (1) NO328713B1 (de)
NZ (1) NZ530495A (de)
PL (1) PL211351B1 (de)
RU (1) RU2294937C9 (de)
WO (1) WO2003011868A1 (de)
ZA (1) ZA200400574B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US7393854B2 (en) * 2003-01-17 2008-07-01 Astrazeneca Ab Thienopyrimidinedinones and their use in modulation of autoimmune disease
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2576168A1 (en) * 2004-08-18 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP2011510030A (ja) * 2008-01-22 2011-03-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−ベンゾイミダゾール類、該化合物を含む医薬、これらの使用及びこれらの製造方法
PE20120834A1 (es) * 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP5990980B2 (ja) * 2012-04-02 2016-09-14 大日本印刷株式会社 オランザピンの中間体の製造方法
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AR117469A1 (es) 2018-12-21 2021-08-11 Merck Patent Gmbh Derivados de alquino disustituidos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
IL136499A0 (en) 1997-12-05 2001-06-14 Astrazeneca Uk Ltd Astrazeneca Pyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pypyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pyridazinone compounds, process for their preparatioridaziones compounds, process for their preparation, pharmaceutical compositions containing them, a n, pharmaceutical compositions containing them, a process for prepating the pharmaceutical compositiprocess for preparing the pharmaceutical compositions, and use thereof ons, and use thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6300334B1 (en) 1998-08-28 2001-10-09 Astrazeneca Ab Thieno[2,3-d]pyrimidine-2,4-diones
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US7393854B2 (en) 2003-01-17 2008-07-01 Astrazeneca Ab Thienopyrimidinedinones and their use in modulation of autoimmune disease
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
IL159785A0 (en) 2004-06-20
NO328713B1 (no) 2010-05-03
PL211351B1 (pl) 2012-05-31
HUP0402336A3 (en) 2008-09-29
AU2002319469B2 (en) 2007-08-09
CA2453274A1 (en) 2003-02-13
HUP0402336A2 (hu) 2005-02-28
WO2003011868A1 (en) 2003-02-13
AU2002319469B8 (en) 2003-02-17
AR038000A1 (es) 2004-12-22
US20040254198A1 (en) 2004-12-16
US20080207642A1 (en) 2008-08-28
ES2292784T3 (es) 2008-03-16
RU2294937C9 (ru) 2007-07-20
BR0211262A (pt) 2004-07-20
EP1414825B1 (de) 2007-09-26
EP1414825B9 (de) 2009-09-16
MY138145A (en) 2009-04-30
NZ530495A (en) 2005-07-29
RU2004102392A (ru) 2005-07-10
GB0118479D0 (en) 2001-09-19
DE60222671D1 (de) 2007-11-08
ZA200400574B (en) 2005-04-26
IS2598B (is) 2010-03-15
IS7118A (is) 2004-01-19
DE60222671T2 (de) 2008-06-26
EP1414825A1 (de) 2004-05-06
PL369232A1 (en) 2005-04-18
RU2294937C2 (ru) 2007-03-10
JP4456364B2 (ja) 2010-04-28
CN1324033C (zh) 2007-07-04
US7384950B2 (en) 2008-06-10
KR100897469B1 (ko) 2009-05-14
MXPA04000677A (es) 2004-04-05
IL159785A (en) 2009-11-18
JP2004538316A (ja) 2004-12-24
HK1065785A1 (en) 2005-03-04
CN1538970A (zh) 2004-10-20
NO20040364L (no) 2004-03-29
KR20040017355A (ko) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE297380T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE447552T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60112791D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
ATE415392T1 (de) Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
EP1465854A4 (de) Chalconderivate und deren verwendung zur behandlung von krankheiten
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
ATE318821T1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60223547D1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE602004010708D1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
ATE323685T1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties